Skip to main content
. 2017 May 25;8(34):56780–56790. doi: 10.18632/oncotarget.18187

Table 2. Meta-analysis of the association between the CASP8 -652 6N ins/del polymorphism and overall cancer risk.

Variables No. of studies Sample size Homozygous Heterozygous Recessive Dominant Allele
DD vs. II ID vs. II DD vs. ID/II ID/DD vs. II D vs. I
OR (95% CI) P het OR (95% CI) P het OR (95% CI) P het OR (95% CI) P het OR (95% CI) P het
All 49 33494/36397 0.76 (0.69-0.84) <0.001 0.87 (0.83-0.92) <0.001 0.82 (0.75-0.89) <0.001 0.85 (0.80-0.90) <0.001 0.87 (0.83-0.91) <0.001
Cancer type
 Colorectal 12 13058/14418 0.93 (0.82-1.05) 0.018 0.94 (0.88-0.99) 0.529 0.96 (0.87-1.06) 0.019 0.93 (0.87-1.00) 0.190 0.96 (0.90-1.01) 0.012
 Breast 8 9943/10271 0.80 (0.67-0.96) 0.001 0.90 (0.81-1.01) 0.018 0.85 (0.74-0.99) 0.002 0.87 (0.77-0.99) 0.002 0.89 (0.80-0.98) <0.001
 Esophageal 3 1412/1196 0.56 (0.40-0.78) 0.901 0.93 (0.74-1.17) 0.206 0.58 (0.42-0.79) 0.812 0.83 (0.71-0.97) 0.385 0.81 (0.72-0.92) 0.712
 RCC 3 903/915 0.39 (0.26-0.59) 0.852 0.78 (0.64-0.95) 0.998 0.46 (0.32-0.66) 0.732 0.71 (0.58-0.86) 0.949 0.70 (0.61-0.82) 0.966
 Lung 2 1585/1544 0.66 (0.51-0.87) 0.473 0.75 (0.64-0.88) 0.385 0.75 (0.59-0.95) 0.458 0.73 (0.63-0.85) 0.453 0.78 (0.69-0.87) 0.273
 Cervical 2 420/824 0.58 (0.36-0.93) 0.456 0.86 (0.59-1.25) 0.230 0.59 (0.39-0.88) 0.728 0.76 (0.59-0.98) 0.355 0.76 (0.63-0.92) 0.556
 Prostate 2 650/205 1.54 (0.67-3.55) 0.100 0.99 (0.79-1.23) 0.411 1.50 (0.74-3.07) 0.135 1.05 (0.85-1.29) 0.321 1.11 (0.93-1.33) 0.255
 Bladder 2 577/618 0.44 (0.25-0.77) 0.799 0.79 (0.62-1.01) 0.334 0.48 (0.27-0.84) 0.907 0.74 (0.59-0.93) 0.317 0.74 (0.61-0.90) 0.338
 Lymphoma 2 139/240 1.19 (0.44-3.23) 0.729 0.82 (0.52-1.31) 0.635 1.26 (0.47-3.39) 0.789 0.86 (0.56-1.34) 0.559 0.93 (0.64-1.35) 0.535
 Gastric 2 196/675 0.35 (0.19-0.63) 0.939 0.74 (0.44-1.23) 0.145 0.45 (0.26-0.78) 0.538 0.64 (0.40-1.01) 0.171 0.66 (0.51-0.84) 0.487
 ALL 2 491/644 1.85 (1.20-2.87) 0.655 1.83 (0.69-4.85) 0.004 1.32 (0.81-2.14) 0.228 1.79 (0.81-3.97) 0.014 1.33 (1.10-1.61) 0.443
 Others 9 4120/4847 0.57 (0.43-0.75) 0.009 0.72 (0.65-0.79) 0.976 0.65 (0.49-0.88) 0.001 0.70 (0.64-0.77) 0.855 0.75 (0.68-0.84) 0.013
Ethnicity
 Asian 27 10569/11219 0.58 (0.48-0.70) <0.001 0.80 (0.75-0.85) 0.231 0.62 (0.52-0.74) 0.002 0.77 (0.72-0.83) 0.016 0.79 (0.73-0.84) <0.001
 Caucasian 20 22689/24796 0.90 (0.83-0.98) 0.006 0.92 (0.88-0.97) 0.225 0.95 (0.89-1.02) 0.007 0.92 (0.87-0.97) 0.079 0.95 (0.91-0.99) 0.008
 African 1 106/257 0.70 (0.35-1.43) / 1.17 (0.62-2.19) / 0.63 (0.37-1.05) / 0.98 (0.54-1.80) / 0.82 (0.60-1.13) /
 Mixed 1 130/125 2.13 (1.01-4.46) / 3.12 (1.70-5.73) / 1.00 (0.54-1.85) / 2.80 (1.57-5.00) / 1.50 (1.05-2.12) /
Source of control
 PB 24 25259/26848 0.83 (0.75-0.92) <0.001 0.89 (0.84-0.94) 0.008 0.89 (0.82-0.96) <0.001 0.87 (0.81-0.93) <0.001 0.89 (0.85-0.95) <0.001
 HB 22 7966/9184 0.61 (0.49-0.75) <0.001 0.83 (0.77-0.89) 0.213 0.67 (0.55-0.82) <0.001 0.79 (0.73-0.87) 0.024 0.81 (0.75-0.88) <0.001
 NM 3 269/365 1.73 (0.95-3.14) 0.619 1.30 (0.53-3.20) 0.003 1.07 (0.63-1.80) 0.896 1.29 (0.58-2.88) 0.005 1.14 (0.79-1.64) 0.156
Quality score
 >9 24 16745/16831 0.67 (0.58-0.77) <0.001 0.81 (0.76-0.87) 0.008 0.75 (0.66-0.85) <0.001 0.78 (0.73-0.84) <0.001 0.81 (0.76-0.87) <0.001
 ≤9 25 16749/19566 0.87 (0.77-0.99) <0.001 0.95 (0.90-1.01) 0.289 0.90 (0.81-1.00) <0.001 0.94 (0.88-1.00) 0.048 0.94 (0.90-0.99) <0.001

Values were in bold, if the 95% CI excluded 1 or P<0.05.

Het: heterogeneity; RCC: renal cell carcinoma; ALL: acute lymphocytic leukemia; HB: hospital based; PB: population based; NM: not mentioned.